Dataset Information

Maternal Vitamin D Status at Week 30 of Gestation and Offspring Cardio-Metabolic Health at 20 Years: A Prospective Cohort Study over Two Decades.

ABSTRACT:

Background/objectives

Vitamin D deficiency is common among pregnant women and since the fetus relies exclusively on maternal supply, deficiency could potentially interfere with fetal development. Vitamin D blood concentrations during pregnancy have been associated with offspring cardio-metabolic health in a few previous studies but the evidence is still inconsistent and only one previous study has followed the offspring into adulthood. The aim of the present study was to investigate the association between maternal serum concentration of vitamin D (25(OH)D) in week 30 of gestation and offspring cardio-metabolic risk factors at 20 years.

Subjects/methods

A follow up study of a Danish birth cohort from 1988-89 (n = 965) was conducted. A blood sample was drawn from the women in week 30 of gestation. In 2008-2009, 95% of the original mother and child dyads could be identified in the central registration registry and were alive and living in Denmark. The offspring were followed up with self-reported anthropometrics (N = 629, 69%) and a clinical examination (N = 410, 45%). Multiple linear regression was used to estimate the association between maternal 25(OH)D and offspring cardio-metabolic risk factors adjusting for potential confounders.

Results

No overall association was observed between maternal 25(OH)D in week 30 of gestation and offspring cardio-metabolic risk factors. However, the analyses did suggest a possible inverse association with blood pressure in females.

Conclusions

No clear association between maternal 25(OH)D concentration in week 30 of gestation and cardio-metabolic risk factors in the 20 year old offspring was found.

SUBMITTER: Rytter D

PROVIDER: S-EPMC5072548 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Maternal Vitamin D Status at Week 30 of Gestation and Offspring Cardio-Metabolic Health at 20 Years: A Prospective Cohort Study over Two Decades.

Rytter Dorte D Bech Bodil Hammer BH Halldorsson Thorhallur Ingi TI Henriksen Tine Brink TB Grandström Charlotta C Cohen Arieh A Olsen Sjurdur Frodi SF

PloS one 20161020 10

<h4>Background/objectives</h4>Vitamin D deficiency is common among pregnant women and since the fetus relies exclusively on maternal supply, deficiency could potentially interfere with fetal development. Vitamin D blood concentrations during pregnancy have been associated with offspring cardio-metabolic health in a few previous studies but the evidence is still inconsistent and only one previous study has followed the offspring into adulthood. The aim of the present study was to investigate the ...[more]

PMID: 27764169

Similar Datasets

Project description:For pharmaceutical companies, it is essential to define their long-term corporate strategy. This especially involves the pipeline progress of pharmaceuticals and portfolio management. The objective of this study was to give a broad overview of study durations of the clinical trials from the top 30 pharmaceutical companies worldwide and to investigate what could possibly impact these study durations (e.g., indication areas, companies themselves, etc.) We worked with the clinicaltrials.gov database to examine the pipeline (phase 1-3) and portfolio (after regulatory approval) of the top 30 pharma companies worldwide over 20 years (from 2000-2020). We further calculated the study duration of each clinical study as the difference between the start date and end date. To analyze changes in our measure we estimated multiple linear regression to evaluate the impact of indication areas and companies on the study duration. Most of the clinical studies were conducted in the areas of ONCIM (N = 2720), and META (N = 1993). The indication with the highest study duration was ONCIM (on average 3.9 years per clinical study, SD: 0.8). Values for the study duration vary widely across companies. Mostly they range between 1 and 4 years (e.g., Merck Sharp & Dohme (MSD) on average 2.2 years per clinical study, SD: 1.0). Correlation analysis showed that study phases were positively correlated with the study duration (+ 0.36, p < 0.000), i.e., the higher the study phase, the higher the study duration. Furthermore, we found that indication areas influenced the study duration significantly (+ 0.17, p < 0.000). However, there were wide variations in effect sizes across indications. The results suggest that different indication areas influence the study duration to different extents. Pipeline progress and portfolio management differ widely between indications, companies and over the years. Research findings could help corporate strategy managers to make more informed decisions regarding their business development strategy.

Dataset Information

Maternal Vitamin D Status at Week 30 of Gestation and Offspring Cardio-Metabolic Health at 20 Years: A Prospective Cohort Study over Two Decades.

Background/objectives

Subjects/methods

Results

Conclusions

Publications

Maternal Vitamin D Status at Week 30 of Gestation and Offspring Cardio-Metabolic Health at 20 Years: A Prospective Cohort Study over Two Decades.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets